Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the regulatory status of a lifespan-extending drug for dogs by the end of 2025?
Approved for veterinary use • 25%
Approved for limited use or specific conditions • 25%
Not approved • 25%
Still under review • 25%
Announcements from regulatory bodies such as the FDA or equivalent organizations
Scientists Develop Drugs, Including mTOR Inhibitor Rapamycin, to Extend Lifespan of Dogs with Implications for Human Longevity
Dec 27, 2024, 05:42 AM
Researchers are exploring new drugs aimed at extending the lifespan of dogs, which may have implications for human longevity. Current studies focus on the development of a pill that could prolong the lives of dogs, with scientists suggesting that similar effects might be applicable to humans. This follows the previous identification of the mTOR inhibitor, Rapamycin, as the only molecule rigorously proven to increase lifespan in healthy mice across various studies. The ongoing research into canine longevity could pave the way for advancements in human health and lifespan extension.
View original story
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in UK and EU • 25%
Approved in UK only • 25%
Not approved in any major market • 25%
Approved in UK, EU, and USA • 25%
Approved in EU • 25%
Approved in both • 25%
Approved in US • 25%
Not approved • 25%
European Medicines Agency (EMA) • 25%
Other • 25%
Therapeutic Goods Administration (TGA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
No progress • 25%
Phase III trial initiation • 25%
BLA submission • 25%
Conditional approval • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Proven effective with significant lifespan extension • 25%
Negative effects or halted trials • 25%
No significant effect on lifespan • 25%
Proven effective with moderate lifespan extension • 25%